Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs

Josiane Bourque, Stéphane Potvin, Josiane Bourque, Stéphane Potvin

Abstract

In recent years, several jurisdictions have revised their regulation policy toward both medical and recreational use of cannabis. These changes have elicited concerns regarding how legalization impacts academic achievement and work performance. This review evaluates the acute and long-term (residual) association between cannabis use and cognitive functioning that underlies poor academic and work performance. Relative to other reviews, this article focuses on cross-over randomized controlled trials and prospective designs given that they allow to test the impairing effects of cannabis exposure at the within-subject level. Acute cannabis cognitive effects are discussed separately for known confounding factors such as levels of delta-9-tetrahydrocannabinol (Δ9-THC), Δ9-THC:cannabidiol ratio, previous cannabis use and, comorbidity with psychosis-spectrum disorders. The cognitive residual effects of cannabis are detailed in relation to duration of abstinence, frequency of use, comorbidity with psychosis-spectrum disorders, types of cognitive domains assessed, and age of cannabis use initiation. Moreover, considering the fact that adequate longitudinal studies can make inferences about causality between cannabis use and impaired cognitive functioning when disentangling between-subject from within-subject variation, proofs for the three main non-mutually exclusive hypotheses about this relationship will be presented: i) the cognitive vulnerability hypothesis as part of the more general common antecedent hypothesis, ii) the concurrent cannabis impairing hypothesis, and iii) the neurotoxic hypothesis of cannabis. Current research provides evidence for mild to moderate acute cannabis effects on episodic and working memory, processing speed, and executive functions. Mild residual impairing effects were also observed in these exact same cognitive domains, suggesting that adverse effects following cannabis intoxication persist at least days or weeks following cannabis abstinence. Relative to adult-onset, adolescent-onset cannabis use seems to explain the dose-response relationship and is associated with longer lasting residual effects even in mild users (<weekly). The association between cannabis and cognition is likely explained by common antecedents, such that genetic and shared environment factors predispose individuals to both cannabis use and cognitive deficits, and to a lesser degree, neurotoxic effects.

Keywords: cannabis; cognition; delta-9-tetrahydrocannabinol; longitudinal design; memory.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Bourque and Potvin.

Figures

Figure 1
Figure 1
Representation of the cognitive vulnerability, concurrent, and neurotoxicity hypotheses relative to the association between cannabis use and cognitive functioning. The cognitive vulnerability hypothesis (represented by the green square) posits that before onset of cannabis use, future cannabis users already exhibit cognitive deficits. The common antecedent hypothesis, which offers a more general framework than the cognitive vulnerability hypothesis, posits that unknown common factors could be responsible for cannabis use onset and mild cognitive deteriorations, without cannabis use being the causal factor of the aforementioned cognitive deficits. Black dotted arrows allow to investigate the neurotoxic hypothesis by testing if previous cannabis use (t−1) predicts subsequent cognitive functioning (t), while controlling for frequency of cannabis use at time t. Lastly, black bidirectional arrows between cognitive abilities and cannabis use at every time-point represent the concurrent hypothesis. Indeed, cognitive performance at time t is associated with cannabis use at time t, without necessarily persisting effects through time.

References

    1. Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. . Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. (2020) 77:165–71. 10.1001/jamapsychiatry.2019.3254
    1. Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS. Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder. Addiction. (2017) 112:1985–91. 10.1111/add.13904
    1. Sarvet al, Wall MM, Fink DS, Greene E, Le A, Boustead AE, et al. . Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. Addiction. (2018) 113:1003–16. 10.1111/add.14136
    1. Dilley JA, Richardson SM, Kilmer B, Pacula RL, Segawa MB, Cerdá M. Prevalence of cannabis use in youths after legalization in Washington state. JAMA Pediatrics. (2019) 173:192–3. 10.1001/jamapediatrics.2018.4458
    1. Wall MM, Mauro C, Hasin DS, Keyes KM, Cerda M, Martins SS, et al. . Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on Stolzenberg et al. (2015) and reanalysis of US national survey on drug use in households data 2002-2011. Int J Drug Policy. (2016) 29:9–13. 10.1016/j.drugpo.2016.01.015
    1. Choo EK, Benz M, Zaller N, Warren O, Rising KL, McConnell KJ. The impact of state medical marijuana legislation on adolescent marijuana use. J Adolesc Heal. (2014) 55:160–6. 10.1016/j.jadohealth.2014.02.018
    1. Cascini F, Aiello C, Di Tanna G. Increasing delta-9-tetrahydrocannabinol (δ−9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev. (2012) 5:32–40. 10.2174/1874473711205010032
    1. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. (2016) 79:613–9. 10.1016/j.biopsych.2016.01.004
    1. Potter DJ, Clark P, Brown MB. Potency of Δ9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. (2008) 53:90–4. 10.1111/j.1556-4029.2007.00603.x
    1. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS ONE. (2013) 8:e70052. 10.1371/journal.pone.0070052
    1. Dujourdy L, Besacier F. A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int. (2017) 272:72–80. 10.1016/j.forsciint.2017.01.007
    1. Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, et al. . Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend. (2010) 110:247–53. 10.1016/j.drugalcdep.2010.03.008
    1. Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the christchurch health and development study. Soc Psychiatry Psychiatric Epidemiol. (2015) 50:1317–26. 10.1007/s00127-015-1070-x
    1. Stiby AI, Hickman M, Munafò MR, Heron J, Yip VL, Macleod J. Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction. (2015) 110:658–68. 10.1111/add.12827
    1. Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction. (2003) 98:685–92. 10.1046/j.1360-0443.2003.00356.x
    1. MacDonald S, Hall W, Roman P, Stockwell T, Coghlan M, Nesvaag S. Testing for cannabis in the work-place: a review of the evidence. Addiction. (2010) 105:408–16. 10.1111/j.1360-0443.2009.02808.x
    1. Bernerth JB, Walker HJ. Altered states or much to do about nothing? A study of when cannabis is used in relation to the impact it has on performance. Gr Organ Manag. (2020) 45:459–78. 10.1177/1059601120917590
    1. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. (2013) 59:478–92. 10.1373/clinchem.2012.194381
    1. Ramaekers JG, Berghaus G, Van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug and Alcohol Depend. (2004) 73:109–19. 10.1016/j.drugalcdep.2003.10.008
    1. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. (2012) 344:e536. 10.1136/bmj.e536
    1. Galve-Roperh I, Palazuelos J, Aguado T, Guzmán M. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. (2009) 259:371–82. 10.1007/s00406-009-0028-y
    1. Zhornitsky S, Pelletier J, Assaf R, Li C, Potvin S. Acute effects of partial CB1 receptor agonists on humans: a meta-analysis of human studies. Prog Neuropsychopharmacol Biol Psychiatry. (2021) 104:110063. 10.1016/j.pnpbp.2020.110063
    1. Broyd SJ, Van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition - a systematic review. Biol Psychiatry. (2016) 79:557–67. 10.1016/j.biopsych.2015.12.002
    1. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fat Acids. (2002) 66:269–85. 10.1054/plef.2001.0351
    1. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJA, et al. . Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. (2015) 25:325–34. 10.1016/j.euroneuro.2014.11.014
    1. Ballard ME, Bedi G, De Wit H. Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J Psychopharmacol. (2012) 26:1289–98. 10.1177/0269881112446530
    1. Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM. The endocannabinoid system and emotional processing: a pharmacological fMRI study with {increment}9-tetrahydrocannabinol. Eur Neuropsychopharmacol. (2013) 23:1687–97. 10.1016/j.euroneuro.2013.06.009
    1. Fusar-Poli P, Crippa J, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. . Distinct effects of A9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. (2009) 66:95–105. 10.1001/archgenpsychiatry.2008.519
    1. Phan KL, Angstadt M, Golden J, Onyewuenyi I, Popovska A, De Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci. (2008) 28:2313–9. 10.1523/JNEUROSCI.5603-07.2008
    1. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. . The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. (2004) 29:1558–72. 10.1038/sj.npp.1300496
    1. Hunault CC, Mensinga TT, Böcker KBE, Schipper CMA, Kruidenier M, Leenders MEC, et al. . Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology. (2009) 204:85–94. 10.1007/s00213-008-1440-0
    1. Curran VH, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology. (2002) 164:61–70. 10.1007/s00213-002-1169-0
    1. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Δ9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. (2006) 85:114–22. 10.1016/j.drugalcdep.2006.03.015
    1. Heishman SJ, Arasteh K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav. (1997) 58:93–101. 10.1016/S0091-3057(96)00456-X
    1. Böcker KBE, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL. Cannabis with high Δ9-THC contents affects perception and visual selective attention acutely: an event-related potential study. Pharmacol Biochem Behav. (2010) 96:67–74. 10.1016/j.pbb.2010.04.008
    1. Hart CL, Van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacol. (2001) 25:757–65. 10.1016/S0893-133X(01)00273-1
    1. Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, et al. . A study investigating the acute dose-response effects of 13 mg and 17 mg Δ 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol. (2008) 22:441–51. 10.1177/0269881108088194
    1. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. . Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open. (2018) 1:e184841. 10.1001/jamanetworkopen.2018.4841
    1. Adam KCS, Doss MK, Pabon E, Vogel EK, de Wit H. Δ9-Tetrahydrocannabinol (THC) impairs visual working memory performance: a randomized crossover trial. Neuropsychopharmacol. (2021) 45:1807–16. 10.1038/s41386-020-0690-3
    1. Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, et al. . Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. (2012) 18:4966–79. 10.2174/138161212802884780
    1. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. (2002) 42:11S−9S. 10.1002/j.1552-4604.2002.tb05998.x
    1. Solowij N, Broyd S, Marie GL, van Hell H, Martelozzo D, Rueb K, et al. . A randomised controlled trial of vaporised Δ 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. (2019) 269:17–35. 10.1007/s00406-019-00978-2
    1. Colizzi M, Bhattacharyya S. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addiction Rep. (2017) 4:62–74. 10.1007/s40429-017-0142-2
    1. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, et al. . A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol. (2011) 26:224–36. 10.1002/hup.1196
    1. Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. (2018) 8:181. 10.1038/s41398-018-0191-x
    1. Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry. (2010) 197:285–90. 10.1192/bjp.bp.110.077503
    1. Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. . Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. (2012) 42:391–400. 10.1017/S0033291711001322
    1. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. . Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. (2013) 27:19–27. 10.1177/0269881112460109
    1. Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, et al. . Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. (2019) 236:2713–24. 10.1007/s00213-019-05246-8
    1. Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM. Psychomotor performance in relation to acute oral administration of Δ9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci. (2009) 259:284–92. 10.1007/s00406-009-0868-5
    1. Lawn W, Freeman TP, Pope RA, Joye A, Harvey L, Hindocha C, et al. . Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational' hypotheses. Psychopharmacology. (2016) 233:3537–52. 10.1007/s00213-016-4383-x
    1. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. . Blunted psychotomimetic and amnestic effects of Δ-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. (2008) 33:2505–16. 10.1038/sj.npp.1301643
    1. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. . Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology. (2008) 198:587–603. 10.1007/s00213-007-1042-2
    1. Colizzi M, McGuire P, Giampietro V, Williams S, Brammer M, Bhattacharyya S. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure. Eur Neuropsychopharmacol. (2018) 28:850–62. 10.1016/j.euroneuro.2018.04.003
    1. Theunissen EL, Kauert GF, Toennes SW, Moeller MR, Sambeth A, Blanchard MM, et al. . Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication. Psychopharmacology. (2012) 220:341–50. 10.1007/s00213-011-2479-x
    1. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. (2009) 23:266–77. 10.1177/0269881108092393
    1. Solowij N, Michie PT. Cannabis and cognitive dysfunction: Parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci. (2007) 32:30–52.
    1. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. . Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. (2005) 57:594–608. 10.1016/j.biopsych.2004.12.006
    1. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, et al. . An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. (2006) 31:2748–57. 10.1038/sj.npp.1301197
    1. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. (2012) 20:420–9. 10.1037/a0029117
    1. Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: a meta-analysis. Exp Clin Psychopharmacol. (2020) 28:471–94. 10.1037/pha0000326
    1. Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of cannabis with cognitive functioning in adolescents and young adults a systematic review and meta-analysis. JAMA Psychiatry. (2018) 75:585–95. 10.1001/jamapsychiatry.2018.0335
    1. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. (2003) 9:679–89. 10.1017/S1355617703950016
    1. Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S. The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med. (2016) 46:177–88. 10.1017/S0033291715001646
    1. Potvin S, Pelletier J, Grot S, Hébert C, Barr A, Lecomte T. Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis. Addict Behav. (2018) 80:154–60. 10.1016/j.addbeh.2018.01.021
    1. Potvin S, Stavro K, Rizkallah É, Pelletier J. Cocaine and cognition: a systematic quantitative review. J Addict Med. (2014) 8:368–76. 10.1097/ADM.0000000000000066
    1. Stavro K, Pelletier J, Potvin S. Widespread and sustained cognitive deficits in alcoholism: a meta-analysis. Addict Biol. (2013) 18:203–13. 10.1111/j.1369-1600.2011.00418.x
    1. Meier MH, Caspi A, Ambler A, Harrington HL, Houts R, Keefe RSE, et al. . Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. (2012) 109: E2657–64. 10.1073/pnas.1206820109
    1. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. (2002) 59:1337–43. 10.1212/01.WNL.0000031422.66442.49
    1. Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, et al. . Effects of extended cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. Neuropsychopharmacology. (2017) 42:2259–71. 10.1038/npp.2017.85
    1. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana - a comparison with pre-drug performance. Neurotoxicol Teratol. (2005) 27:231–9. 10.1016/j.ntt.2004.11.003
    1. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J Clin Pharmcol. (2002) 42:41S-7S. 10.1002/j.1552-4604.2002.tb06002.x
    1. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. (2001) 58:909–15. 10.1001/archpsyc.58.10.909
    1. Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav. (2010) 35:970–6. 10.1016/j.addbeh.2010.06.012
    1. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. (2011) 128:111–6. 10.1016/j.schres.2011.02.017
    1. Yücel M, Bora E, Lubman DI, Solowij N, Brewer WJ, Cotton SM, et al. . The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. (2012) 38:316–30. 10.1093/schbul/sbq079
    1. Sánchez-Gutiérrez T, Fernandez-Castilla B, Barbeito S, González-Pinto A, Becerra-García JA, Calvo A. Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning. Eur Psychiatry. (2020) 63:e6. 10.1192/j.eurpsy.2019.9
    1. Ferraro L, La Cascia C, Quattrone D, Sideli L, Matranga D, Capuccio V, et al. . Premorbid adjustment and iq in patients with first-episode psychosis: a multisite case-control study of their relationship with cannabis use. Schizophr Bull. (2020) 46:517–29. 10.1093/schbul/sbz077
    1. Rabin RA, Zakzanis KK, Daskalakis ZJ, George TP. Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Res. (2013) 206:158–65. 10.1016/j.psychres.2012.11.019
    1. Castellanos-Ryan N, Pingault JB, Parent S, Vitaro F, Tremblay RE, Séguin JR. Adolescent cannabis use, change in neurocognitive function, and high-school graduation: a longitudinal study from early adolescence to young adulthood. Dev Psychopathol. (2017) 29:1253–66. 10.1017/S0954579416001280
    1. Morin JFG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, et al. . A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry. (2019) 176:98–106. 10.1176/appi.ajp.2018.18020202
    1. Infante MA, Nguyen-Louie TT, Worley M, Courtney KE, Coronado C, Jacobus J. Neuropsychological trajectories associated with adolescent alcohol and cannabis use: a prospective 14-year study. J Int Neuropsychol Soc. (2020) 26:480–91. 10.1017/S1355617719001395
    1. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al. . Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc Natl Acad Sci USA. (2016) 113:E500–8. 10.1073/pnas.1516648113
    1. Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, et al. . Associations between adolescent cannabis use and neuropsychological decline: a longitudinal co-twin control study. Addiction. (2018) 113:257–65. 10.1111/add.13946
    1. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: Preliminary findings of a longitudinal study of effects on IQ in young adults. Can Med Assoc J. (2002) 166:887–91.
    1. Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran HV. Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol. (2016) 30:159–68. 10.1177/0269881115622241
    1. Paige KJ, Colder CR. Long-term effects of early adolescent marijuana use on attentional and inhibitory controlle. J Stud Alcohol Drugs. (2020) 81:164–72. 10.15288/jsad.2020.81.164
    1. Boccio CM, Beaver KM. Examining the influence of adolescent marijuana use on adult intelligence: Further evidence in the causation versus spuriousness debate. Drug Alcohol Depend. (2017) 177:199–206. 10.1016/j.drugalcdep.2017.04.007
    1. Edalati H, Krank MD. Childhood maltreatment and development of substance use disorders: a review and a model of cognitive pathways. Trauma Violence Abus. (2016) 17:454–67. 10.1177/1524838015584370
    1. Isen J. A meta-analytic assessment of Wechsler's P>V sign in antisocial populations. Clin Psychol Rev. (2010) 423–35. 10.1016/j.cpr.2010.02.003
    1. Tarter RE, Kirisci L, Mezzich A, Cornelius JR, Pajer K, Vanyukov M, et al. . Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder. Am J Psychiatry. (2003) 160:1078–85. 10.1176/appi.ajp.160.6.1078
    1. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction. (2011) 106:2195–203. 10.1111/j.1360-0443.2011.03574.x
    1. Jacobus J, Squeglia LM, Alejandra Infante M, Castro N, Brumback T, Meruelo AD, et al. . Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: a three-year longitudinal study. Neuropsychology. (2015) 29:829–43. 10.1037/neu0000203
    1. Moffitt T, Meier M, Caspi A, Poulton R. Reply to rogeberg and daly: no evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. Proc Natl Acad Sci USA. (2013) 110:E980–2. 10.1073/pnas.1300618110
    1. Ross JM, Ellingson JM, Rhee SH, Hewitt JK, Corley RP, Lessem JM, et al. . Investigating the causal effect of cannabis use on cognitive function with a quasi-experimental co-twin design. Drug Alcohol Depend. (2020) 206: 107712. 10.1016/j.drugalcdep.2019.107712
    1. Meier MH. Cannabis use and psychosocial functioning: evidence from prospective longitudinal studies. Curr Opin Psychol. (2021) 38:19–24. 10.1016/j.copsyc.2020.07.001
    1. Cerdá M, Moffitt TE, Meier MH, Harrington HL, Houts R, Ramrakha S, et al. . Persistent cannabis dependence and alcohol dependence represent risks for midlife economic and social problems: a longitudinal cohort study. Clin Psychol Sci. (2016) 4:1028–46. 10.1177/2167702616630958
    1. McKetin R, Parasu P, Cherbuin N, Eramudugolla R, Anstey KJ. A longitudinal examination of the relationship between cannabis use and cognitive function in mid-life adults. Drug Alcohol Depend. (2016) 169:134–40. 10.1016/j.drugalcdep.2016.10.022
    1. Auer R, Vittinghoff E, Yaffe K, Künzi A, Kertesz SG, Levine DA, et al. . Association between lifetime marijuana use and cognitive function in middle age the coronary artery risk development in young adults (CARDIA) study. JAMA Intern Med. (2016) 176:352–61. 10.1001/jamainternmed.2015.7841
    1. Becker MP, Collins PF, Schultz A, Urošević S, Schmaling B, Luciana M. Longitudinal changes in cognition in young adult cannabis users. J Clin Exp Neuropsychol. (2018) 40:529–43. 10.1080/13803395.2017.1385729
    1. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol. (1999) 149:794–800. 10.1093/oxfordjournals.aje.a009894
    1. Cengel HY, Bozhurt M, Evren C, Umut G, Keskinkilic C, Agachanli R. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Res. (2018) 262:46–54. 10.1016/j.psychres.2018.01.046

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner